Entheon Biomedical is a psychedelic-drug development company focused on treating substance-use disorder. We are committed to the legal development of safe & effective psychedelic medicines, and in educating the public and medical profession as to the efficacy of psychedelic protocols when clinically administered in the optimum set and setting.
Aware of the growing crisis of substance-use disorder and overdose all over the world, Entheon is developing a DMT therapeutic protocol that will be specifically tailored to address the core mechanisms underlying drug-seeking and using behavior. Our chief aim is to provide an effective and scalable therapeutic protocol that will serve as a vital resource for those afflicted with a substance-use disorder who are wanting to reclaim their lives.
Read more about Entheon Biomedical
Timothy Ko | CEO@Entheon Biomedical
Timothy Ko, CEO, Entheon Biomedical. Timothy Ko has a broad background of leading private ventures in the Service Sector, Investor Relations, Retail and Technology. Most recently he served as Director of Hyperbridge Technology, a company focused on the development of decentralized technologies that facilitate crowdfunding.
Timothy’s passion for the psychedelic space is shaped by firsthand knowledge of the shortcomings of the current mental health and substance-use treatment models, and through his exposure to psychedelics, which he credits with saving his life. Following the loss of a loved one to a decades’ long fight with mental health and addictions, and through his personal experiences, Timothy is driven to develop and commercialize the life saving potential of psychedelic medicines.